Latest Capital Raises News

Pacific Edge Limited (ASX – PEB) has announced a securities purchase plan (SPP) aiming to raise up to NZD 5 million, contingent on shareholder approval of a prior NZD 16 million placement. The move is designed to bolster working capital amid ongoing growth initiatives.

Dreadnought Resources Limited reported a solid cash flow quarter ending June 2025, with a net cash increase of AUD 3.1 million and a funding runway extending to five quarters. The company’s financial position reflects strategic financing activity amid ongoing exploration investments.

Dreadnought Resources has fortified its balance sheet with an $8.5 million capital raise and secured a $15 million joint venture with Teck Resources, advancing its Mangaroon gold and critical minerals projects.

Complii FinTech Solutions reported an 11.8% increase in customer receipts for Q4 FY25, alongside a 4.3% quarterly rise in annual recurring revenue, underscoring its expanding footprint in capital raising and compliance software.

betr Entertainment has unveiled an all-scrip takeover bid for PointsBet, offering shareholders 3.81 betr shares per PointsBet share, valuing the offer above a competing cash bid and promising significant cost synergies.

betr Entertainment Limited has launched an all-scrip takeover bid for PointsBet Holdings Limited, offering 3.81 betr shares for every PointsBet share, valuing PointsBet at $1.22 per share and promising significant cost synergies.

Kula Gold Limited has reported impressive high-grade gold drilling results at its Mt Palmer Gold Mine, completing an 80% JV earn-in, while progressing exploration at Kirup and securing a niobium project approval in Malawi. The company faces a tight cash position but is actively managing funding.

Rapid Critical Metals has completed its capital consolidation and placement, reshaping its issued capital structure with shareholder approval.

Imugene Limited has launched a $37.5 million equity raising through a Placement and Share Purchase Plan, offering new shares and options to fund its pivotal azer-cel clinical program. The raise includes attaching and piggyback options, subject to shareholder approval, aiming to bolster the company’s immuno-oncology pipeline.

Imugene Limited has launched a A$37.5 million capital raising to advance its promising off-the-shelf CAR T therapy, azer-cel, following encouraging Phase 1b data showing a 75% overall response rate in lymphoma patients.

Imugene Limited has completed a $22.5 million institutional placement and launched a $15 million Share Purchase Plan, both featuring attaching options, to fund its azer-cel clinical program through a pivotal trial in 2026.

Caspin Resources has completed the second tranche of its $2.1 million capital raising, issuing shares and free-attaching options approved by shareholders. The move strengthens funding for its diverse Australian mineral projects.